Company intelligence / Profile preview

Seer

Redwood City, California, United Statesseer.cancer.gov ↗

Ownership: Public · SEER
Employees: ~134
Development stage: Commercial

Overview

Seer's Proteograph Product Suite enables deep, unbiased, high-throughput mass spectrometry-based proteomics. The latest workflow processes over 1,000 samples per week per instrument with reduced cost and increased reproducibility. The technology is used in population-scale studies to discover biomarkers and understand disease biology but is not itself a therapeutic or diagnostic product

Modalities: DeviceNanoparticleSoftware (for data analysis)
Industry: Non-Drug Biotech

Partnerships

BiodesixDiscovery Life SciencesEvotecSanford Burnham Prebys Medical Discovery InstituteSoulbrainSciex

Financials

Market cap: $106.1M
Total revenue: $3.1M
Enterprise value: $-24.3M

Beyond the preview

Go deeper on Seer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seer.

Explore the full profile